Studio clinico NCT02194738 · Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Studio clinico NCT02194738 risulta «attivo (non in reclutamento)» su ClinicalTrials.gov.
Patologia: Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7 · Interventi registrati: Carboplatin, Cisplatin, Crizotinib, Erlotinib, Gemcitabine Hydrochloride, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed, Pemetrexed Disodium · Date registrate (fonte): 2014-09-26, 2026-09-28, 2014-07-18, 2026-08-28.
Sintesi dello studio (fonte: ClinicalTrials.gov, testo originale in inglese):
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.